Business Wire

NY-DILIGENT

10.8.2021 13:47:07 CEST | Business Wire | Press release

Share
Diligent Introduces the Most Comprehensive ESG Solution on Modern GRC Platform

Diligent Corporation , the global leader in SaaS governance, risk and compliance (GRC), announced today the launch of the marketplace’s most comprehensive ESG software solution – Diligent ESG – on its governance, risk, and compliance (GRC) platform. Diligent ESG is powered in part by the newly announced acquisition of Accuvio and builds on the company’s recent acquisitions of Galvanize and Steele Compliance.

Diligent’s holistic, purpose-built ESG platform will empower organizations to address the seminal components of ESG that matter most to their stakeholders as they strive to meet current reporting requirements while also planning and preparing for the future. The solution will act as a nexus for ESG data from diverse sources to support goal setting, risk monitoring and stakeholder reporting, including to the board of directors, across diversity, climate, workforce safety, third-party risk, cyber, and more.

“Leaders today face an uphill battle in trying to establish impactful ESG programs and demonstrate progress: lack of clarity around where to start, manual processes with data in disparate systems, and a fragmented reporting landscape,” said Brian Stafford, CEO of Diligent. “Now, they can count on Diligent’s agile platform to track their risk, compliance, and ESG data in one place, establish ESG targets, and implement the governance structures to achieve those targets. With a comprehensive ESG solution at their fingertips, our clients will be able to respond with confidence to evolving regulations and investor preferences through a broader GRC practice.”

“It’s no secret that current business information systems are not designed with ESG reporting in mind,” said Matt DiGuiseppe, head of Diligent’s ESG Center of Excellence. “We are excited to offer a solution that can transform information scattered across even the most complex multinational organizations into a comprehensive, actionable ESG dataset, leverages mature capabilities battle-tested for over 30 years in the audit and compliance world.”

With Diligent ESG, public and private organizations – regardless of where they are in their program maturity – will have a sophisticated solution to help them build and enhance their ESG program, evaluate and track progress toward their goals, and integrate the data into their corporate strategy. Key features and functionality will include:

  • Automated data collection through robotic process automation that connects to multiple internal platforms and monitors performance against ESG objectives in real time
  • Collection, calculation, and reporting of greenhouse gas (GHG) emissions across the entire value chain (scopes, 1, 2, and 3) – all in a way that is completely auditable
  • Customizable reports and real-time dashboards support clear, consistent communication with internal and external stakeholders, including regulators, focused on ESG performance
  • Seamless connection of internal ESG data with third-party data, facilitating benchmarking relative to peers and the market
  • Validation of how ESG programs are impacting public sentiment and assessing governance practices and executive compensation against a database of global peers, leveraging Diligent’s data and analytics

To learn more about the Diligent ESG solution, visit: https://diligent.com/solutions/esg

About Diligent Corporation
Diligent is the leading governance, risk and compliance (GRC) SaaS provider, serving more than one million users from over 25,000 organizations around the globe. Our modern GRC platform ensures boards, executives and other leaders have a holistic, integrated view of audit, risk, information security, ethics and compliance across the organization. Diligent brings technology, insights and confidence to leaders so they can build more effective, equitable and successful organizations.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye